Mason & Associates Inc Sells 820 Shares of Edwards Lifesciences Co. (NYSE:EW)

Mason & Associates Inc lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 10.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,062 shares of the medical research company’s stock after selling 820 shares during the quarter. Mason & Associates Inc’s holdings in Edwards Lifesciences were worth $523,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. lifted its holdings in shares of Edwards Lifesciences by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after purchasing an additional 273 shares in the last quarter. Nordea Investment Management AB lifted its stake in Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after buying an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its holdings in shares of Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after buying an additional 300,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Edwards Lifesciences by 9.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock valued at $31,571,000 after buying an additional 40,348 shares during the period. Finally, AIA Group Ltd raised its holdings in shares of Edwards Lifesciences by 91.7% during the third quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock worth $49,461,000 after acquiring an additional 358,556 shares during the period. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on EW shares. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Royal Bank of Canada raised their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday, December 5th. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 11th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Finally, Truist Financial reissued a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and an average price target of $78.48.

Edwards Lifesciences Stock Down 2.1 %

Edwards Lifesciences stock opened at $68.79 on Thursday. The firm has a 50 day moving average price of $71.82 and a two-hundred day moving average price of $71.62. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The firm has a market cap of $40.57 billion, a price-to-earnings ratio of 9.93, a PEG ratio of 3.77 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.59 earnings per share. Equities analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,500 shares of company stock valued at $2,160,800 over the last ninety days. 1.27% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.